ment for prostate cancer [13, 14] . The D'Amico risk stratification system is widely utilized in the American Urologic Association and National Comprehensive Cancer Network guidelines, and is often used to determine eligibility for clinical trials [15, 16] . Specifically, placement in the high-risk group is often a primary inclusion criterion of neoadjuvant clinical trials [17, 18] . Publications have examined the differences in outcomes of D'Amico risk categories based on primary and secondary biopsy Gleason score (BGS) [19] .
Using a large, prospectively maintained prostatectomy cohort, we reviewed pathologic and intermediate-term biochemical outcomes of patients after prostatectomy stratified by D'Amico risk classification and sub-stratified by primary and secondary BGS.
Patients and Methods
We queried a prospectively maintained, institutional review board-approved database for all patients undergoing robotic-assisted laparoscopic prostatectomy (RALP) between January 2006 and June 2013. The start date was selected to correspond with the adoption of the 2005 modification of the Gleason score by the International Society of Urological Pathologists by our dedicated genitourinary pathologists [20] . Patients were first stratified by D'Amico risk classification, and then the intermediate-risk (IR) group was sub-stratified by BGS (3 + 3 = 6, 3 + 4 = 7, and 4 + 3 = 7). Only patients with sufficient clinical data to determine D'Amico risk stratification were included in the analysis.
When possible, external biopsy slides underwent internal pathologic review. In total, 65% (1,442/2,226) of patients had either their biopsies performed at our institution or biopsy slides reviewed by our dedicated genitourinary pathologists. For the purposes of this study, external biopsy results were deemed adequate if the initial report provided Gleason primary and secondary score, total number of positive cores, and greatest percentage of tumor volume in a given core. There were no patients in the cohort who were excluded based on these external biopsy inclusion criteria, and all patients with externally reviewed biopsies were included in our analysis.
Patients were assigned a D'Amico risk classification using standard guidelines: low (PSA < 10 ng/ml, BGS 6, and clinical stage cT1c or cT2a); intermediate (PSA 10 ng/ml but < 20 ng/ml, BGS = 7, or clinical stage cT2b); high (PSA 20 ng/ml, BGS 8, or clinical stage cT2c/cT3) [9] . All prostatectomy specimens were sectioned into 4 quadrants and mounted in the standard fashion. Surgical margins were recorded as positive if there was tumor at the inked margin. If positive surgical margins were present, patients were dichotomized as having focal or extensive invasion, defined as less than or equal to and greater than 2 mm of invasion, respectively. Patients were followed after surgery in the routine fashion, and PSA levels were typically checked at 6 weeks postoperatively, then every 3 months for the first year, every 6 months for the subsequent 2 years, and annually beginning 3 years postoperatively. Biochemical recurrence (BCR) was defined as a single PSA measurement of > 0.2 ng/ml beyond 6 weeks postoperatively. Use, type, and date of initiation of any secondary treatments after prostatectomy were documented.
Comparisons between groups were performed using ANOVA for continuous variables and chi square for categorical variables. Biochemical disease-free survival (BDFS) was estimated using Kaplan-Meier curves, and differences between groups were calculated through log rank analysis. Multivariable logistic regression models, controlling for BGS, preoperative PSA, and clinical stage as appropriate were fitted to predict BCR, while Cox proportional hazard regression models were used to assess the association between these clinical variables and disease-free survival. Preoperative PSA was stratified into 3 groups for the purpose of these analyses: 0-10 ng/ml, 11-20 ng/ml, and > 20 ng/ml. All statistical analyses were performed using SPSS version 19.0 (IBM, Armonk, NY, USA). Because of the PSA ( 10 ng/ml) and/or clinical stage (cT2b) requirement of Gleason 6 patients to be classified as IR, IR BGS 3 + 3 patients had a higher median PSA (11.9 ng/ml, p < 0.001). Concordance between BGS and pathologic Gleason score varied between biopsies performed or reviewed at our institution and those that were externally scored. Internal versus external concordance rates for IR patients with BGS 3 + 3, 3 + 4, and 4 + 3 were 29 vs. 53%, 76 vs. 73%, and 41 vs. 44%, respectively (all p < 0.001).
Results

Between
Pathologic outcomes for IR patients sub-stratified by BGS are presented in (11) 108 (10) 109 (12) 23 (9.5) Other 154 (7) 66 (6) 65 (7) 23 ( vs. 7%, p < 0.001), but there was no significant difference in the rate of 3-year BDFS (95 vs. 95%, p = 0.71). Generally, pathologic outcomes were worse with increasing BGS, including higher stage and positive surgical margins (p < 0.05).
BDFS after a median follow-up of 13.5 months was significantly different between all D'Amico risk categories as illustrated in figure  1 , with worsening BDFS as either the D'Amico classification or the primary Gleason score increased (p < 0.001). Overall BDFS was not significantly different between D'Amico low-risk patients and IR BGS 6 patients (p = 0.71). However, BDFS was superior in D'Amico low-risk patients when compared to both IR BGS 3 + 4 and BGS 4 + 3 patients (p = 0.001 and p < 0.001, respectively). Likewise, BDFS was also worse among D'Amico IR patients with BGS 4 + 3 when compared to IR patients with BGS 3 + 3 and BGS 3 + 4 (p = 0.05 and p = 0.003). D'Amico high-risk patients had significantly lower BDFS rates than all other classifications, including the worst IR subgroup, BGS 4 + 3 (p < 0.001).
The use of androgen deprivation therapy (ADT) or radiation as secondary treatment was more common with increasing D'Amico risk groups (p < 0.001). Among D'Amico IR patients, secondary treatments were only used in those with BGS 3 + 4 or 4 + 3. However, among those IR patients who did receive ADT or radiation, there was no difference in the type of secondary treatment used. The majority received salvage external beam radiotherapy, with or without adjuvant ADT. When comparing the number of patients who received adjuvant and salvage approaches, there was no differ- In multivariate logistic regression analyses, BGS remained a significant predictor of BCR, as did PSA level. When controlling for PSA, age, and clinical stage, the risk of BCR in IR patients with BGS 4 + 3 was significantly higher than in IR patients with either a BGS of 3 + 4 or 3 + 3 (odds ratio (OR) 1.9, 95% confidence interval (CI) 1.05-3.43, p = 0.03; OR 8.6, 95% CI 1.79-41.44, p = 0.007, respectively). In these analyses, there was no difference in BCR between IR patients with a BGS of 3 + 3 or 3 + 4. Among our IR patients, increasing PSA from less than 10 ng/ml to 11-20 ng/ml carried a higher risk of BCR (OR 4.9, 95% CI 2.49-9.96, p < 0.001) when controlling for clinical stage, age, and BGS. These results remained significant when controlling for patients whose biopsies were not reviewed at our institution.
A second multivariate analysis using Cox regression was conducted to validate our logistic regression analysis (table 3) . BGS was a predictor of BDFS among IR patients when controlling for PSA and clinical stage with worse outcomes among IR 4 + 3 patients compared to IR 3 + 3, (hazard ratio (HR) 8.9, 95% CI 2.00-39.85, p = 0.004). There was no significant difference in BDFS between IR BGS 6 patients and low-risk patients (OR 0.516, 95% CI 0.12-2.32, p = 0.39) or between IR BGS 3 + 4 and IR BGS 4 + 3 patients (OR 1.696, 95% CI 0.90-2.95, p = 0.10). In our Cox regression, we did find a difference in BDFS between IR BGS 6 and IR BGS 3 + 4 (HR 5.267, 95% CI 1.16-23.86, p = 0.03). When controlling for BGS and clinical stage and using the low PSA group as a reference, increasing preoperative PSA from 11-20 ng/ml to > 20 ng/ml was predictive of BDFS (OR 3.457, CI 2.18-5.48, p < 0.001; OR 2.741, CI 1.62-3.25, p < 0.001, respectively).
Discussion
This study was performed to assess the oncologic outcome of 2,226 patients undergoing RALP in different D'Amico risk classifications. By comparing outcomes of D'Amico IR patients sub-stratified by BGS, we found significant heterogeneity in pathologic and biochemical outcomes. Our study has 2 primary findings. First, D'Amico IR patients with BGS 6 behave quite similarly to D'Amico low-risk patients, and superior to their IR counterparts with a Gleason 4 component. Second, IR patients with BGS 4 + 3 have worse pathologic outcomes and lower rates of BDFS than IR patients with lower Gleason scores. Although their outcomes are superior to those classified as D'Amico high-risk patients, they nonetheless represent a fairly high-risk cohort.
The morphologic and architectural appearance of prostate cancer glands as first described by Donald Gleason remains arguably the most important prognostic indicator in prostate cancer, though the original grading system has evolved since the original description [21] [22] [23] . The Gleason score is incorporated into risk classification systems and nomograms to help predict histopathologic findings and the likelihood of disease recurrence following therapeutic intervention [8] [9] [10] [11] [12] . We examined the predictive ability of BGS in determining pathologic outcomes, BDFS, and freedom from secondary intervention for D'Amico IR patients.
Though often considered as a single entity, Gleason 7 tumors have been found to be a heterogeneous group whose outcomes differ with the primary Gleason pattern. It has been well described that pathologic Gleason score 4 + 3 has worse outcomes in terms of disease-free survival and prostate cancer-specific mortality than Gleason 3 + 4 [5, 6, [24] [25] [26] [27] [28] . However, the body of literature examining differences in outcomes based on primary biopsy Gleason pattern in Gleason 7 tumors is limited [29, 30] . Interestingly, our analysis also showed that each group of IR patients had a statistically different follow-up duration. Patients in higher D'Amico groups were less likely to be followed up for an extended period of time. In practice, patients with worse prostate cancer will likely be referred to a secondary treatment specialist, such as a radiation oncologist. Considering the high rates of survival in prostate cancer, it is unlikely that loss of follow-up in higher-risk patient arises from prostate cancer-specific deaths.
Similarly to our study, Makarov et al. [31] described the differences in Gleason 7 tumors stratified by primary Gleason score in a cohort of 537 men and found that a BGS 4 + 3 was associated with a higher pathologic stage (p < 0.016) and had a higher incidence of PGS 8 when compared to BGS 3 + 4 (22.3 vs. 9.3%). Khoddami et al. [32] also found worse pathologic findings, specifically a higher likelihood of upgrading, with BGS 4 + 3 compared to 3 + 4 (p < 0.001). The Shared Equal Access Regional Cancer Hospital radical prostatectomy database when risk-stratified by BGS 7-10 and BGS 4 + 3 was associated with increased odds of seminal vesicle invasion (p < 0.001) and extra capsular extension (p = 0.01) compared to BGS 3 + 4 [33] . In contrast to our findings, they did not find a significant difference for pathologic outcome when comparing BGS 4 + 3 to 4 + 4 or higher. Using multivariate analysis, they demonstrated that patients with BGS 4 + 3 were more likely to experience BCR than patients with BGS 3 + 4 (HR 2.08, p = 0.001) but found no difference in recurrence compared to BGS 4 + 4 or higher. Our findings support these earlier studies, but also demonstrate a significant heterogeneity of outcomes within patients assigned to the IR category by D'Amico criteria.
There are several published and validated systems to preoperatively approximate the risk of BCR and prostate cancer-specific mortality [8-12, 28, 34] . While generally similar, each of these nomograms uses somewhat distinct variables and methodology to assign risk. The D'Amico system, as described above, as well as the frequently used Partin tables include clinical stage, total BGS, and preoperative PSA [9, 11] . The Cancer of the Prostate Risk Assessment (CAPRA) score incorporates these variables but also primary and secondary biopsy Gleason patterns and age [8] . The Stephenson nomogram (update of the Kattan nomogram) [35] adds up the number of positive and negative cores and primary and secondary biopsy Gleason patterns [8, 12] . The Han tables assign BDFS probability based on primary and secondary Gleason patterns and preoperative PSA values [10, 11] . While each instrument has its flaws, it is only the D'Amico risk classification system that is formally recommended by the American Urologic Association in their update of guidelines for the management of localized prostate cancer [9, 16] .
The D'Amico system has been extensively validated to show that it predicts both the risk of recurrence and prostate cancer-specific mortality [13, 14, 36, 37] . However, in a comparison between the predictive abilities of the D'Amico risk classification system, the CAPRA score, and the Stephenson nomogram, the D'Amico classification system was found to have the least concordance with actual outcomes at 3 and 5 years [38] . Our results demonstrate the heterogeneity of the D'Amico IR group, and suggest that the overall performance of the classification system could perhaps be improved with a sub-stratification of the IR group by incorporating primary biopsy Gleason pattern. It also is possible that the absence of the BGS from the D'Amico risk classification system may exclude patients who might otherwise be considered high risk and eligible for entrance into various clinical trials. We did not formally evaluate the other instruments, and it is possible that 1 or more of them may have performed superiorly in predicting outcomes in our cohort.
The majority, but not all biopsy specimens were reviewed by a central pathologist. However, slides reviewed externally tended to be more accurate at predicting pathologic Gleason score at prostatectomy. Patients in this study were all treated at an academic institution by a single surgeon, and the findings may not be generalizable to the overall population. Partly as an effect of limiting our entrance criteria to patients operated on after the 2005 modification of the Gleason score by the International Society of Urological Pathologists, our median follow-up is relatively short at 13.5 months. Increased follow-up may alter our results in light of the prolonged natural history of prostate cancer. Finally, despite being a relatively large single institution study, we still may be underpowered to demonstrate differences in outcomes between some of our subgroups, though our findings generally appear robust. 
Conclusion
We demonstrated significant heterogeneity of pathologic and biochemical outcomes among patients with D'Amico IR prostate cancer. IR patients with BFS 6 appear to have identical intermediate-term BDFS as low-risk patients. Increasing BGS from 3 + 3 to 3 + 4 to 4 + 3 results in a higher likelihood of locally advanced disease and intermediate-term biochemical failure. IR patients with BGS 4 + 3 have worse pathologic and biochemical outcomes than other IR patients independent of PSA levels and clinical stage. D'Amico IR patients demonstrate significant heterogeneity in both pathologic outcomes and BDFS. Primary biopsy Gleason pattern remains a powerful prognostic indicator in localized prostate cancer, also within the D'Amico IR patients. Our findings may have implications in terms of considerations in counseling, and suggest the possibility of sub-stratification within the commonly used D'Amico risk strata to improve its prognostic accuracy. External validation with larger, longer series would be necessary to further assess these findings.
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